Alyeska Investment Group L.P. Invests $4.76 Million in Acelyrin, Inc. (NASDAQ:SLRN)

Alyeska Investment Group L.P. purchased a new position in shares of Acelyrin, Inc. (NASDAQ:SLRN - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 1,515,878 shares of the company's stock, valued at approximately $4,760,000. Alyeska Investment Group L.P. owned approximately 1.51% of Acelyrin at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of SLRN. Almitas Capital LLC increased its position in shares of Acelyrin by 506.5% in the fourth quarter. Almitas Capital LLC now owns 148,704 shares of the company's stock valued at $467,000 after buying an additional 124,185 shares in the last quarter. 4WEALTH Advisors Inc. purchased a new stake in shares of Acelyrin in the fourth quarter valued at $35,000. Northern Trust Corp increased its position in Acelyrin by 3.8% during the 4th quarter. Northern Trust Corp now owns 630,051 shares of the company's stock worth $1,978,000 after purchasing an additional 23,130 shares in the last quarter. Boothbay Fund Management LLC lifted its holdings in Acelyrin by 54.8% in the 4th quarter. Boothbay Fund Management LLC now owns 29,828 shares of the company's stock valued at $94,000 after purchasing an additional 10,554 shares in the last quarter. Finally, Susquehanna Fundamental Investments LLC acquired a new stake in shares of Acelyrin during the 4th quarter worth about $746,000. Institutional investors and hedge funds own 87.31% of the company's stock.

Acelyrin Stock Down 4.1 %

Shares of SLRN traded down $0.10 on Friday, hitting $2.36. 395,887 shares of the stock traded hands, compared to its average volume of 1,202,568. Acelyrin, Inc. has a 1 year low of $1.85 and a 1 year high of $7.25. The stock's 50 day moving average is $2.46 and its two-hundred day moving average is $3.11. The firm has a market capitalization of $238.14 million, a P/E ratio of -0.96 and a beta of 1.07.

Acelyrin (NASDAQ:SLRN - Get Free Report) last posted its quarterly earnings data on Wednesday, March 19th. The company reported ($0.79) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.86) by $0.07. Research analysts forecast that Acelyrin, Inc. will post -2.53 EPS for the current year.

Insider Transactions at Acelyrin

In other Acelyrin news, CEO Mina Kim sold 17,986 shares of the business's stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $2.74, for a total transaction of $49,281.64. Following the completion of the sale, the chief executive officer now owns 671,753 shares of the company's stock, valued at approximately $1,840,603.22. The trade was a 2.61 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 13.60% of the company's stock.

About Acelyrin

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.